Last week, the lobbying group AdvaMed pushed back on the firings, calling on Health Secretary Robert F. Kennedy Jr. to ...

Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDA ...

Years ago, he had a good-paying job working from home as an accountant. But isolated from the office, he said he fell into a depression and began to lose himself in a shady corner of the dark web ...

This research shows that by manipulating just this one protein, scientists could potentially reverse cellular aging – ...

There's an arms race in medicine—scientists design drugs to treat lethal bacterial infections, but bacteria can evolve ...

A paper in the Journal of the National Cancer Institute finds that almost 20% of patients in middle-stage cancer drug trials ...

FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the ...

There's an arms race in medicine – scientists design drugs to treat lethal bacterial infections, but bacteria can evolve defenses to those drugs, sending the researchers back to square one.

Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...